Non-exclusive rebate agreement for Atomoxetine (excluding oral solution)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Atomoxetin exklusive der Darreichung Lösung (ATC-Code nach WHO: N06BA09)
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities; actual demand depends on prescription and dispensing behavior.
Buyer may terminate if exclusive agreements are concluded (typically within 8-12 months).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Sep 30, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2027
- Non-exclusive pharmaceutical rebate agreements for Atomoxetine (excluding oral solution)
- Open-house model - all eligible pharmaceutical companies may participate
Show full summary
Non-exclusive drug rebate agreement for Atomoxetine (N06BA09) under §130a(8) SGB V via an open-house model. Open to all pharmaceutical companies that meet eligibility. No guaranteed volume or exclusivity. Rolling submission until 30 September 2027. Buyer: AOK PLUS for Saxony and Thuringia.
Risks
No minimum purchase quantities; actual demand depends on prescription and dispensing behavior.
Buyer may terminate if exclusive agreements are concluded (typically within 8-12 months).
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company as defined in §4(18) AMG for the offered medicines
Eligibility
- Must submit declaration regarding exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)
Administrative
- Must submit declaration regarding Russia sanctions (Eigenerklärung Russlandsanktionen)
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive rebate agreement for Atomoxetine (excluding oral solution)
Conclusion of non-exclusive rebate agreement for the active substance Atomoxetine (ATC N06BA09), excluding oral solution. Open-house model, no individual negotiations, no exclusivity.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Atomoxetin exklusive der Darreichung Lösung (ATC-Code nach WHO: N06BA09)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 30 Jun 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 449660-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities; actual demand depends on prescription and dispensing behavior.
Buyer may terminate if exclusive agreements are concluded (typically within 8-12 months).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications